Publicaciones (104) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer

    International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77

  2. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  3. A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

    Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715

  4. A method using 4D dose accumulation to quantify the interplay effect in lung stereotactic body radiation therapy

    Physics in Medicine and Biology, Vol. 66, Núm. 3

  5. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  6. A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 434-449

  7. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial

    International Journal of Gynecological Cancer, Vol. 31, Núm. 4, pp. 617-622

  8. A proteomic atlas of lineage and cancer-polarized expression modules in myeloid cells modeling immunosuppressive tumor-infiltrating subsets

    Journal of Personalized Medicine, Vol. 11, Núm. 6

  9. Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26

  10. Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors

    Cancers, Vol. 13, Núm. 15

  11. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  12. Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?

    Clinical and Translational Oncology, Vol. 23, Núm. 3, pp. 536-542

  13. Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology

    ESMO Open

  14. Body shape trajectories and risk of breast cancer: Results from the SUN ('Seguimiento Universidad de Navarra') Project

    Public Health Nutrition, Vol. 24, Núm. 3, pp. 467-475

  15. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  16. Cancer survivors referred to a long-term survivorship outpatient service within academic medical oncology: descriptive study

    Journal of Cancer Survivorship, Vol. 15, Núm. 6, pp. 811-817

  17. Caso 2. Intimidad

    Manual de casos con pacientes estandarizados para el ECOE (Editorial Médica Panamericana), pp. 11-12

  18. Caso 24. Oncología

    Manual de casos con pacientes estandarizados para el ECOE (Editorial Médica Panamericana), pp. 78-80

  19. Caso 4. Profesionalismo: error médico sin consecuencias para el paciente

    Manual de casos con pacientes estandarizados para el ECOE (Editorial Médica Panamericana), pp. 15-16

  20. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial

    ESMO Open, Vol. 6, Núm. 2